Innovations and clinical trials in prostate cancer from SUO 2021

“[Polygenic risk scores] will help augment PSA screening and other tools to really figure out when we should initiate prostate cancer screening in men and how frequently that screening should occur,” says Isla Garraway, MD, PhD.

In this video, Isla Garraway, MD, PhD, discusses the latest innovations and promising clinical trials in the prostate cancer space. These ideas were focused on in the session on early detection and treatment of prostate cancer that was presented at the 2021 Society of Urological Oncology Annual Meeting. Garraway is an associate professor and director of research in the department of urology, and a member of the Jonsson Comprehensive Cancer Center and Broad Center for Regenerative Medicine at the UCLA School of Medicine in Los Angeles, California.